A feasibility study on the development of Psorax35 as the first and only oral treatment for mild-to-moderate psoriasis with positive effects on co-morbidities.

Project description

Development of the first oral treatment for mild-to-moderate psoriasis

According to the World Health Organisation, there is an urgent demand for an efficient and safe psoriasis drug that could be used without necessitating a close monitoring of the patient. Available drugs do not have satisfactory efficacy and often cause serious side effects. The EU-funded PsoraxPlan project aims to develop and deliver Psorax35 as an efficient drug for mild and moderate cases of psoriasis. If Psorax35 proves efficient against psoriasis, it could also have a positive effect on comorbidities such as arthritis and cardiovascular complications. The objective for the first phase of the whole project is to deliver a comprehensive feasibility analysis of this drug for the treatment of mild-to-moderate psoriasis.

Fields of science

• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs
• medical and health sciences › clinical medicine › cardiology › cardiovascular diseases

Programme(s)

• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

• EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-SMEInst-2018-2020-1
See other projects for this call

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

ARCTIC NUTRITION AS

Address

Industrivegen 42
6155 Orsta
Norway

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU contribution

€ 50 000